Last reviewed · How we verify
TR-701 FA tablets
At a glance
| Generic name | TR-701 FA tablets |
|---|---|
| Also known as | Torezolid Phosphate Tablet |
| Sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Headache
- Abscess
- Vomiting
- Cellulitis
- Diarrhea
- diarrhea
- Abscess limb
- Dizziness
- Diarrhoea
- cellulitis
- abscess
Key clinical trials
- A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects (PHASE1)
- A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study (PHASE2)
- TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (PHASE3)
- TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections (PHASE3)
- Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects (PHASE1)
- Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: